CVS Caremark will update its commercial formularies effective July 1, 2026, to prefer FDA-approved interchangeable biosimilars over certain brand-name drugs, including switching from Stelara to biosimilars Pyzchiva and Yesintek. This change aims to reduce drug costs for clients and members, often resulting in $0 out-of-pocket expenses for patients. The update expands biosimilar coverage in specialty areas like multiple sclerosis and rare blood disorders, supporting affordability and access while maintaining clinical quality. CVS Caremark will provide communication and support to ensure a smooth transition for all stakeholders.
This week, investors focus on key inflation data with Thursday's core PCE price index report, the Fed's preferred inflation gauge, expected at 3.3%, influencing rate decisions under new Fed Chair Kevin Warsh. A series of Federal Reserve speeches will...
Glenview Capital has reduced its holdings in CVS Health by 3.75 million shares following strong Q1 results and raised annual guidance, after the stock gained 80% since their initial investment in May 2024. Despite the reduction, CVS remains one of Gl...
CVS Health has invested $9 million in the development of The Mews at St. Mary, a new 75-unit affordable senior housing complex in Williamstown, New Jersey. This project, in partnership with the Diocesan Housing Services Corporation, The Walters Group...
CVS Health has announced a renewed commitment to support military-connected individuals and families through a comprehensive approach that includes healthcare access, community programs, and economic opportunities. Partnering with organizations like ...
